Biotech News
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
investors.arcutis.com2026-05-06 20:03 EST
Q1 2026 net product revenue for ZORYVE ® (roflumilast) was $105.4 million, a 65% increase compared to Q1 2025, and a 17% decrease compared to Q4 2025 Continued strong demand for ZORYVE despite typical Q1 seasonality, with continued growth in share of branded non-steroidal topical treatments